Navigation Links
Low-Dose Aspirin After Lung Clot Could Prevent Recurrence

SATURDAY, Dec. 10 (HealthDay News) -- Giving low-dose aspirin to patients after they've received stronger blood thinners for dangerous clots in the lungs could cut their odds of redeveloping the clots, a new study finds.

The clots in question are venous thromboembolisms (VTEs). These can include both the leg clots known as deep-vein thromboses, or pulmonary embolisms, clots in the lungs that can cause rapid pulse, shortness of breath, chest pain and even death.

Patients with VTE are typically given anticoagulants such as warfarin (Coumadin) to help prevent future clots and dissolve existing clots in the veins. However, about 15 to 20 percent of VTE patients redevelop blood clots within two years after completing such treatment, according to background information in the study.

Extending blood thinner treatment with powerful medicines such as warfarin can prevent recurrences, but it also carries an increased risk of bleeding. So, the longer term use of aspirin as an alternative therapy against recurrent blood clots in VTE patients has been advocated but is controversial. That's because aspirin is typically used to prevent clots in the arteries, not the veins, and studies have yielded mixed findings about the aspirin's effectiveness against VTEs.

This new study examined whether two years of low-dose (100 milligrams per day) aspirin therapy after an initial six to 12 months of warfarin therapy could prevent recurrent blood clots in VTE patients. The patients were followed for up to three years after completing their aspirin therapy.

The Italian researchers reported that blood clots recurred in 28 of the 205 patients who took aspirin and in 43 of the 197 patients who took a placebo -- 6.6 percent versus 11.2 percent per patient-year, respectively.

Major bleeding occurred in one patient in each group and there was a similar rate of non-major bleeding.

The study was scheduled to be presented Saturday at the annual meeting of the American Society of Hematology (ASH) in San Diego.

"There has been significant debate on whether giving aspirin to a patient who suffers from VTE is beneficial," lead author Dr. Cecilia Becattini, an assistant professor of internal medicine in the Internal and Cardiovascular Medicine and Stroke Unit at the University of Perugia, said in an ASH meeting news release. "Our study shows that aspirin, a common and low-cost drug found in most medicine cabinets, can be a valid alternative to oral anticoagulants for the extended treatment of VTE."

Experts reacted positively to the new findings.

"This is a very important trial demonstrating a safe and effective alternative to long-term warfarin to reduce the incidence of recurrent venous thromboembolism," said Dr. Robert Lookstein, director of cardiovascular imaging at Mount Sinai Medical Center in New York City. "This trial shows that a simple medication such as once-a-day aspirin can safely reduce the risk of recurrent DVT and protect patients against these devastating consequences," he added.

But another expert noted an important caution. "It should be emphasized that this does not replace the initial treatment of VTE, which is heparin or warfarin anticoagulation," said Dr. Glenn Jacobowitz, vice-chair of the vascular surgery division at NYU Langone Medical Center in New York City. "In my practice I would consider recommending low-dose aspirin after warfarin anticoagulation courses are finished for VTE. Patients should ask their physician about switching to lifetime low-dose aspirin after finishing a standard six- to 12-month course of warfarin anticoagulation for VTE."

Data presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.

More information

The American Academy of Family Physicians has more about deep vein thrombosis.

-- Robert Preidt

SOURCES: Glenn Jacobowitz, M.D., vice-chair, vascular surgery division, NYU Langone Medical Center, New York City; Robert Lookstein, M.D., director, cardiovascular imaging, Mount Sinai Medical Center, and associate professor, Mount Sinai School of Medicine, New York City; American Society of Hematology, news release, Dec. 10, 2011

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Even low-dose aspirin may increase risk of GI bleeding
2. Screening with low-dose spiral CT scanning reduces lung cancer deaths by 20 percent
3. New Blood Thinner Beats Plavix When Paired With Low-Dose Aspirin
4. Low-dose sorafenib may improve therapy for head and neck cancer
5. Low-dose chest CT effective in reducing radiation for evaluation of cardiothoracic surgery patients
6. Risk of cancer increases with exposure to low-dose radiation
7. Small bowel blood flow in healthy subjects receiving low-dose aspirin
8. Low-Dose Aspirin Boosts Accuracy of Colon Cancer Test
9. Low-dose aspirin reduces death rates from range of cancers by between 20 and 30 percent
10. Low-Dose Aspirin May Reduce Colon Cancer Risk
11. Low-Dose Omega-3 Fatty Acids Dont Protect Heart Patients
Post Your Comments:
Related Image:
Low-Dose Aspirin After Lung Clot Could Prevent Recurrence
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, ... for the Narconon network, announced the release of a new cutting edge recovery program ... organization has been working with drug- and alcohol-addicted individuals with the purpose to free ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... , ... In an ongoing Clinical Study conducted by an independent physician, Andrew ... is evaluating the efficacy of its product and its disinfection protocol. This study is ... May 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary ... Periwinkle Pioneers, nominated by the public, will receive special recognition throughout 2016 as ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... 2015 --> ... devices was valued at $11,171.1 million in 2014, and ... 5.7% during 2015 - 2022. The global market is ... of diabetes. In addition, the increase in obese population ... to the growth of the market. Furthermore, technological advancements ...
Breaking Medicine Technology: